Proteomics and mass spectrometry for cancer biomarker discovery.
Proteomics is a rapidly advancing field not only in the field of biology but also in translational cancer research. In recent years, mass spectrometry and associated technologies have been explored to identify proteins or a set of proteins specific to a given disease, for the purpose of disease detection and diagnosis. Such biomarkers are being investigated in samples including cells, tissues, serum/plasma, and other types of body fluids. When sufficiently refined, proteomic technologies may pave the way for early detection of cancer or individualized therapy for cancer. Mass spectrometry approaches coupled with bioinformatic tools are being developed for biomarker discovery and validation. Understanding basic concepts and application of such technology by investigators in the field may accelerate the clinical application of protein biomarkers in disease management.
Lu
Ming
M
Gonda/UCLA Breast Cancer Research Laboratory.
Faull
Kym F
KF
Whitelegge
Julian P
JP
He
Jianbo
J
Shen
Dejun
D
Saxton
Romaine E
RE
Chang
Helena R
HR